FDA News and Research

RSS

Scientists Reveal How Surface Acids Prevent Bacteria From Blobbing

Researchers have discovered how acids on the surface of bacteria give these microscopic organisms their characteristic "rod" shape-by keeping an enzyme at bay that would otherwise turn the cylindrical cells into shape-shifting blobs.

27 May 2026

High-Resolution Cryo-EM Imaging Reveals a Hidden Secondary Drug Binding Site on Bacterial Ribosomes

A new Nature Communications study, published May 19, redefines scientists' understanding of how a popular class of antibiotics work.

22 May 2026

DNA-Guided CRISPR Technology Enhances Precision and Reduces Off-Target Effects

A team of engineers at the University of Florida has developed a new form of CRISPR technology that could make diagnostics and treatments safer, more precise and more affordable, while opening the door to entirely new ways of controlling disease.

15 May 2026

Prime Assembly Enables Precise Insertion of Large DNA Segments Into the Genome

Researchers at UMass Chan Medical School have developed a gene editing technology that allows for the precise and efficient insertion of very large DNA segments into the human genome.

13 May 2026

New Data Suggest Ready-to-Eat Meats Rarely Reach Illness-Linked Bacterial Levels

The study found that Clostridium perfringens was occasionally detected in raw or not-ready-to-eat meat products, but rarely appeared at concerning levels in cooked ready-to-eat meats. Even products linked to cooling deviations did not exceed 2 log CFU/g, suggesting that illness-associated growth during commercial stabilization is highly unlikely.

13 May 2026

Metabolic Pathway Loss Makes Cancer Cells Vulnerable to PARP Drugs

Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.

5 May 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).

From MRM Health NV 4 May 2026

New Pistoia Alliance Poll Finds Regulatory Teams Benefit Most from AI, But Just 1 % See Value in the Wet Lab

The Pistoia Alliance, a global, not-for-profit that advocates for greater collaboration in life sciences R&D, has released new poll data from its annual European conference, revealing that while AI use is becoming widespread across life sciences organizations, its measurable impact on drug R&D remains limited.

From The Pistoia Alliance 29 Apr 2026

Fragment-Based Drug Design Accelerates Efficient Discovery of New Medicines

Modern medicine has played a significant role in improving the length and quality of our lives. While many treatments may seem like miracles, they are the result of a lengthy, rigorous research process.

24 Apr 2026

Experimental Flu Vaccine That Protects Against Multiple Strains in Mice

According to a study published by investigators at Georgia State University’s Institute for Biomedical Sciences, a novel vaccine platform has been created to generate broad, protective immunity against multiple influenza virus infections, demonstrating potential as an effective mucosal vaccination approach.

6 Apr 2026

Meech Announces Industry-First UL-Certified Hyperion 314IPS Hygienic Ionizing Bar

Meech International has announced the Hyperion 314IPS hygienic ionizing bar as the first of its kind to achieve UL 62368-1 certification.

From Meech International 2 Apr 2026

Nonviral Nanoparticles Show Promise for Safer Gene Delivery Methods

In a demonstration that helps pave the way for gene therapies with fewer side effects, several human cell types were genetically modified with protein nanoparticles designed at University of Michigan Engineering and Michigan Medicine.

1 Apr 2026

The Future of Vision Restoration With ReVision Implant

ReVision Implant is pioneering neuroprosthetic technology to restore vision in blind patients using advanced cortical implants and flexible electrode arrays.

26 Mar 2026

Engineered Bacteria Deliver Targeted Anticancer Therapy in Tumors

Every year, millions of people are diagnosed with cancer globally; however, current treatments are limited by disease complexity.

18 Mar 2026

Blood Tau217 Test Predicts When Alzheimer’s Symptoms May Begin

The %p-tau217 biomarker in blood offers a novel approach to estimate Alzheimer's onset, potentially transforming prevention trial strategies.

5 Mar 2026

Research Shows Successful Recovery of Antigen-Specific T Cells in Mouse Models

Researchers at The Jackson Laboratory (JAX), in collaboration with the Massachusetts Institute of Technology (MIT), have developed the first bandage-like microneedle patch that can sample the body's immune responses painlessly from the skin. The device detects inflammatory signals within minutes and collects specialized immune cells within hours without the need for blood draws or surgical biopsies.

3 Mar 2026

Study Reveals New Structural Role for HIV Integrase

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

19 Feb 2026

Expanding the Biosynthetic Capabilities of Microbes Using Light

Researchers are continually looking for new ways to hack the cellular machinery of microbes like yeast and bacteria to make products that are useful for humans and society.

2 Feb 2026

Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a $257 million Series D financing co‑led by investment funds managed by BlackRock and Eclipse, bringing the company's total capital raised to $612 million.

From Cellares 30 Jan 2026

Trojan Horse Drug Works in Combination With Copper to Kill Bacteria

A research team at the University of Arizona College of Medicine – Tucson is developing a drug that works in combination with copper to kill bacteria, including those that cause MRSA, a type of staph infection that is resistant to usual treatments.

24 Jan 2026